Last updated: February 22, 2026
What Is the Drug and Market Context?
NDC 00054-4179 corresponds to Doxorubicin Hydrochloride Injection, USP. It is an anticancer agent used primarily in chemotherapy protocols for various cancers, including breast cancer, ovarian cancer, and Hodgkin’s lymphoma.
The drug is a generic version of the branded Doxil and Adriamycin brands. It competes in the chemotherapeutic market with other cytotoxic agents and targeted therapies.
Market Size and Demand Drivers
- Prevalence of Target Cancers: Breast cancer affects approximately 300,000 women annually in the U.S., with a significant subset eligible for doxorubicin-based protocols. Ovarian cancer incidence reaches around 20,000 cases per year.
- Treatment Protocols: Doxorubicin remains a frontline agent; its use is often in combination therapy.
- Reimbursement Environment: Medicare and private payers largely reimburse chemotherapy drugs at negotiated rates, impacting net pricing.
Market Players and Competition
- Brand Names: Doxil, Adriamycin.
- Generics: Multiple manufacturers produce generic doxorubicin hydrochloride injections.
- Competitive Factors: Supply reliability, regulatory compliance, and price impact market share.
Regulatory Status
- FDA Approval: Approved for cancer treatment.
- Manufacturing: Several manufacturers hold FDA approval for this formulation, with some producing under Abbreviated New Drug Applications (ANDAs).
Price Trends and Projections
Current Market Pricing (As of Q1 2023)
| Source |
Average WAC (Wholesale Acquisition Cost) per Vial |
Typical Vial Size |
| Federal Supply Schedule |
$45–$55 |
50 mg vial |
| Commercial Pharmacies |
$50–$60 |
50 mg vial |
Note: Actual prices paid by providers vary based on discounts and contracts. Private sector prices tend to be 10-15% higher than federal levels.
Historical Price Trends (Last 5 Years)
- Prices mostly stable between $45–$55 per 50 mg vial.
- Slight declines observed in 2020–2021 attributed to increased competition and generic proliferation.
- Post-pandemic supply chain disruptions temporarily increased prices but stabilized by mid-2022.
Future Price Projections (2023–2027)
- Moderate Price Stability: Prices expected to remain within $45–$60 per vial.
- Downward Pressure: Increased competition, biosimilar development, and procurement pressures tend to reduce margins.
- Potential Price Increases: Rare, driven by manufacturing costs or regulatory compliance costs, but unlikely before 2025.
Influencing Factors on Future Prices
- Regulatory Changes: Patent expirations for branded versions shift focus to generics, exerting downward pressure.
- Manufacturing Costs: Stability expected due to mature production processes.
- Market Competition: Entry of biosimilars or improved formulations may further reduce prices.
- Supply Chain Dynamics: Global supply chain disruptions in raw materials could temporarily inflate costs.
Market Entry and Investment Considerations
- Barriers to Entry: High regulatory hurdles; established generic manufacturers dominate.
- Market Saturation: The market's maturity limits significant price gains.
- Potential for Portfolio Expansion: Combination with other agents in fixed-dose regimens could influence sales volume but not necessarily price.
Summary of Price Projections
| Year |
Predicted Price Range per 50 mg Vial |
Key Influences |
| 2023 |
$45–$55 |
Competitive pressures |
| 2024 |
$45–$55 |
Stable supply, ongoing generics |
| 2025 |
$45–$52 |
Biosimilars potentially entering |
| 2026 |
$44–$50 |
Market saturation |
| 2027 |
$44–$50 |
Cost pressures, regulatory factors |
Key Takeaways
- Doxorubicin Hydrochloride Injection (NDC 00054-4179) faces a mature market with stable pricing.
- Prices hover around $45–$60 per 50 mg vial, with slight downward pressures expected over the coming years.
- Competition from generics and biosimilars enhances price stability and reduction.
- Supply chain stability and regulatory changes remain critical factors influencing future price trends.
- Limited market growth opportunities exist due to the drug's established role in chemotherapy protocols.
FAQs
1. How does the entry of biosimilars affect doxorubicin prices?
Biosimilar entry can reduce prices by increasing competition and offering lower-cost alternatives. However, biosimilars for cytotoxic agents like doxorubicin are less common due to complex manufacturing.
2. Are there significant regional price variations for this drug?
Yes. Prices differ based on provider contracts, buy-back agreements, and regional procurement policies. Federal prices tend to be lower than private sector prices.
3. What regulatory factors could impact future prices?
Patent expirations, FDA approvals for generics or biosimilars, and changes in manufacturing standards influence pricing.
4. How does procurement volume influence price?
Higher procurement volumes typically secure discounts, lowering per-unit costs for large healthcare systems and government agencies.
5. Could drug shortages impact prices?
Shortages can cause temporary price spikes, but supply is currently stable for this drug due to multiple manufacturers.
References
[1] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
[2] IQVIA. (2023). National Drug Estimated Annual Sales & Prices.
[3] Drug Channels Institute. (2022). U.S. Hospital & Retail Prices for Oncology Drugs.
[4] Medicare Part B Drug Average Sales Price Data. (2023).
[5] Evaluate Pharma. (2022). Oncology Market Forecasts.
